SOUTH SAN FRANCISCO, Calif., June 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) announced today that it has received milestone payments totaling $1 million from Merck & Co., Inc. based on progress to date in the companies’ 2004 collaboration to explore ubiquitin ligases, a new class of drug target, to find treatments for cancer and potentially other diseases.
